Article Text

Download PDFPDF
DNA-ploidy and mutant p53 overexpression in primary fallopian tube cancer
  1. A.-C. HELLSTRÖM*,
  2. J. HUE*,
  4. G. AUER
  1. *Department of Gynaecology and Oncology, Radiumhemmet
  2. Department of Tumor Pathology, Karolinska Hospital and Institute, Stockholm, Sweden
  1. Address for correspondence: Ann-Cathrin Hellström, Department of Gynaecology and Oncology, Radiumhemmet, Karolinska Hospital, S-171 76 Stockholm, Sweden.


Nuclear DNA content and p53 immunoreactivity were determined in 53 cases of primary fallopian tube cancer (PFTC). All tumors showed a distinctly aneuploid DNA distribution pattern, whereas p53 immunoreactivity was observed in 51% of the cases. If the patients were divided into two groups according to survival time, p53 immunoreactivity was present in 40% of the tumors from patients surviving for more than 8 years and in 65% of tumors from patients who died within 2 years. This difference was not statistically significant (P = 0.438). Patient survival was significantly correlated to the clinical stage (FIGO) (P = 0.0009).

  • p53
  • ploidy
  • primary fallopian tube cancer
  • staging

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • This study was supported by the Cancer Society in Stockholm.